Market Cap 833.00M
Revenue (ttm) 236.88M
Net Income (ttm) 88.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 17.67
Profit Margin 37.21%
Debt to Equity Ratio 0.00
Volume 200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 13.17M
Stochastic %K N/A
Beta 0.21
Analysts Sell
Price Target $73.00

Company Profile

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company a...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 61 606 11 11
Address:
Hegenheimermattweg 167b, Allschwil, Switzerland
Latest News on BPMUF
No data available.